Clinical trial
Safety and Efficacy of Basiliximab in Calcineurin Inhibitor Intolerant Long-term…
NCT00284947 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00284947 |
|---|---|
| Title | Safety and Efficacy of Basiliximab in Calcineurin Inhibitor Intolerant Long-term Kidney Transplant Recipients Treated With Mycophenolic Acid and Steroids |
| Official title | REPLACE: Safety and Efficacy of Basiliximab in Calcineurin Inhibitor Intolerant Long-term Kidney Transplant Recipients Treated With Mycophenolic Acid and Steroids |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Kidney Transplantation, Adverse Effects |
| Intervention type | Drug |
| Interventions | basiliximab, MMF/EC-MPS, Corticosteroids |
| Enrollment | 7 |
| Start date | Jan 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Feb 1, 2006 |
| Last update posted | Mar 29, 2017 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: